All GLG News Analyses Filed Under: Endocrinology

This is a blood glucose monitoring system with integrated testing supplies (blood strips and lancing) in one compact meter, currently NOT FDA approved. Product was recently shown during the American Diabetes Association Annual Scientific Sessions meeting and exhibits in San Francisco.

Another agent that lowers HBA1C by 0.02% is not a big deal.  There are already too many of these products on the market, none of which do much of anything to improve diabetes care. 

A direct comparison between liraglutide and exenatide is the best way to show liraglutide's true benefit as a GLP-1 analogue. Novo Nordisk did just that and the results bode well for liraglutide. Once daily liraglutide will soon replace exenatide, given its equivalent efficacy in reducing HbA1c and...

As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...

A valuable piece of information indicating an achievement to regulate and control severity of type 2 Diabetes. The article reports the findings of a clinical trial in details, the interesting outcome of weight loss in addition to blood sugar reduction may serve as indicators of possible success for...

Once a week treatment for diabetes with no weight gain.

Amylin's once-weekly version of Byetta, exenatide LAR is based on PLC/PLGC microsphere technology for sustained release of exenatide. It will be used to replace the current twice-daily version and will be favorable in competing against Novo Nordisk’s liraglutide. Additional competition will come from...

Calling a 0.89% improvement "significant" just seems to me to show the weakness of this current trial.  Anyone can use statistics to prove just about anything.  Using verbal manipulation to puff up a study's result is unfair, unreliable and just plain sad.

GLP-1(glucagon like peptide), Exenatide (Byetta) and Liraglutide are incretin mimetics hormones. They have similar action of mechanism such as increase insulin release from pancreas, decrease glucagon production, expand beta cells, and decrease stomach acid secretion and motility and increase food satiety....

The therapy of type 2 DM is burdened by the fact that many meds lose efficacy after time and insulin is required. These results  suggest that Exenitide may indeed not lose efficacy .